期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 11, 期 12, 页码 2007-2016出版社
ELSEVIER
DOI: 10.1016/j.intimp.2011.08.012
关键词
Scopoletin; Angiogenesis; FGF-2; Human umbilical vein endothelial cells; VEGF
资金
- National Natural Science Foundation of China [30672471]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Jiangsu Province Education Department
Previous work in our laboratory has shown that scopoletin, one of the main bioactive constituents of Erycibe obtusifolia Benth stems, exerts anti-arthritic activity in vivo partly by preventing synovial angiogenesis. The present study was performed to further investigate the anti-angiogenic potential of scopoletin, focusing on the mechanisms of action in vitro. In the aortic ring sprouting assay, scopoletin (10, 30 and 100 mu M) significantly inhibited the growth of endothelial sprouts in a concentration-dependent manner. As to human umbilical vein endothelial cells (HUVECs), scopoletin could inhibit their proliferation, migration and tubule formation induced by FGF-2, especially the proliferation. It also remarkably decreased the expression of VEGF at mRNA and protein levels, and the phosphorylations of IKK alpha and I kappa B but not Akt, as well as the degradation of I kappa B caused by FGF-2 in HUVECs. These findings suggest that scopoletin is substantially able to attenuate FGF-2-induced angiogenesis, and it might act by directly preventing the stimulation action of FGF-2 and by indirectly decreasing the production of VEGF. Scopoletin down-regulated the VEGF expression through NF-kappa B rather than PI-3K/Akt signaling pathway. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据